BIOMAT Database Logo BIOMAT Database Logo

Refractory polymyositis undergoing remission following antitubercular therapy. 2015

Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Opportunistic infections pose a significant problem in patients receiving immunosuppressive therapy for autoimmune diseases. We present a case of a woman with polymyositis refractory to high-dose steroid and methotrexate, as a consequence of which she developed miliary tuberculosis. Her myositis went into remission after initiation of antitubercular therapy, in spite of bringing down the intensity of immunosuppression. This is the first reported case of myositis undergoing remission after treating intercurrent infection, and illustrates the complex relationship between autoimmune disease and host response to infection.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
[Recurrence following antitubercular therapy].
January 1986, Zeitschrift fur arztliche Fortbildung,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Pulmonary fibrosis masking polymyositis. Remission with corticosteroid therapy.
November 1972, JAMA,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Rituximab as therapy for refractory polymyositis and dermatomyositis.
May 2006, The Journal of rheumatology,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Update on therapy for refractory dermatomyositis and polymyositis.
November 1996, Current opinion in rheumatology,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus.
March 2023, Rheumatology (Oxford, England),
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Relapse of polymyositis after prolonged remission.
August 1997, The Journal of rheumatology,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
[Pure megaloblastic refractory anemia. Prolonged complete remission following androgenotherapy].
January 1983, Nouvelle revue francaise d'hematologie,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
CD25 blockade for refractory polymyositis.
January 2013, Clinical and experimental rheumatology,
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Refractory polymyositis responding to infliximab.
September 2004, Rheumatology (Oxford, England),
Durga Prasanna Misra, and Sukesh Edavalath, and Abhra Chandra Chowdhury, and Vikas Agarwal
Efficacy of rituximab in dermatomyositis and polymyositis refractory to conventional therapy.
January 2013, Reumatologia clinica,
Copied contents to your clipboard!